Bromodomain and extra-terminal protein inhibitor combination therapy

Patent metadata

Field	Value
Publication number	US-11464771-B2
Application number	US-202017033311-A
Country	US
Kind code	B2
Filing date	Sep 25, 2020
Priority date	Oct 27, 2016
Publication date	Oct 11, 2022
Grant date	Oct 11, 2022

Abstract

The present disclosure relates generally to compositions and methods of treating neoplastic diseases or cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising a combination of, or administering a combination of, a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination, or combination therapy, can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared with the administration of either the BET inhibitor or the chemotherapeutic agent alone.

First claim

We claim:

1. A method for treating cancer or neoplastic disease comprising administering to a human patient a therapeutically effective amount of:
(i) at least one bromodomain and extra-terminal protein (BET) inhibitor; and
(ii) at least one chemotherapeutic agent, which does not inhibit BET directly, wherein the BET inhibitor has the structure of Formula I, or a pharmaceutically acceptable salt thereof,

wherein:
R 2 is CH 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 F, CHF 2 , CF 3 , CH 2 D, CHD 2 , or CD 3 ;
X 5 is C—R 5 , wherein:
R 5 is hydrogen, halogen, OH, CN, OR 61 , NHR 61 , N(R 61 ) 2 , alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, in which
each R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;

X 6 is C—R 6 , wherein:
R 6 is hydrogen, halogen, OH, CN, alkyl, cycloalkyl, cycloalkylalkyl, amino, alkylamino, dialkylamino, cycloalkylalkylamino, alkoxy, or cycloalkylalkoxy;

X 7 is C—R 7 , wherein:
R 7 is hydrogen, halogen, OH, CN, OR 61 , NHR 61 , N(R 61 ) 2 , alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;

X 8 is C—R 8 , wherein
R 8 is hydrogen, halogen, or alkyl; and

R A is

wherein:
X 2 is or C—R 12 , wherein R 12 is hydrogen, halogen, alkyl, or alkoxy;
R 13 is Y—Z, wherein
Y is selected from a bond, CH 2 , CH(C 1 -C 4 alkyl); and
Z is selected from SO 2 R 21 , N(R 22 )SO 2 R 21 , SO 2 N(R 22 ) 2 , N(R 22 )SO 2 N(R 22 ) 2 , CON(R 22 ) 2 , N(R 22 )CO 2 R 21 , N(R 22 )CON(R 22 ) 2 , N(R 22 )COR 21 , COR 21 , OC(O)N(R 22 ) 2 , OSO 2 N(R 22 ) 2 , or N(R 22 )SO 3 R 21 ; wherein
each R 21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; and
each R 22 is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;

X 3 is C—R 14 , wherein R 14 is hydrogen, halogen, —CN, alkyl, cycloalkyl, or alkoxy; and
X 4 is C—R 15 , wherein R 15 is hydrogen, halogen, alkyl, CN, or alkoxy; and
R 16 is hydrogen, halogen, or W—X, wherein
W is a bond, O, or S, and
X is selected from alkyl, aryl, aralkyl, cycloalkyl, cyclo-alkylalkyl, alkynyl, cycloalkylalkynyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl;

wherein the chemotherapeutic agent is selected from the group consisting of temozolomide, romidepsin, and protein-bound paclitaxel, wherein the BET inhibitor is present in an amount to enhance the therapeutic effect of the chemotherapeutic agent, and the cancer or neoplastic disease is selected from the group consisting of non-Hodgkin's lymphoma, leukemia, non-small cell lung cancer, pancreatic cancer, breast cancer, NUT carcinoma, and medulloblastoma.

2. The method of claim 1 , wherein administering the BET inhibitor and the chemotherapeutic agent results in a synergistic reduction in cell proliferation in a tumor of the patient, or a synergistic increase in apoptosis in a tumor of the patient, as compared with administration of either the BET inhibitor or the chemotherapeutic agent alone.

3. The method of claim 1 , wherein the therapeutic effective amount for both the BET inhibitor and chemotherapeutic agent when administered together can be at least 50% lower than that when the BET inhibitor and chemotherapeutic agent are used individually.

4. The method of claim 1 , wherein the chemotherapeutic agent is temozolomide.

5. The method of claim 1 , wherein the chemotherapeutic agent is romidepsin.

6. The method of claim 1 , wherein the chemotherapeutic agent is protein-bound paclitaxel.

7. The method of claim 1 , wherein the cancer or neoplastic disease is non-Hodgkin's lymphoma.

8. The method of claim 1 , wherein the cancer or neoplastic disease is leukemia.

9. The method of claim 1 , wherein the cancer or neoplastic disease is non-small cell lung cancer.

10. The method of claim 1 , wherein the cancer or neoplastic disease is pancreatic cancer.

11. The method of claim 1 , wherein the cancer or neoplastic disease is breast cancer.

12. The method of claim 1 , wherein the cancer or neoplastic disease is NUT carcinoma.

13. The method of claim 1 , wherein the at least one bromodomain and extra-terminal protein (BET) inhibitor is 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one or the pharmaceutically acceptable salt thereof.

14. The method of claim 1 , wherein the cancer is temozolomide-resistant.

15. The method of claim 1 , wherein the cancer or neoplastic disease is medulloblastoma.

Assignees

• Celgene Quanticel Res Inc

Inventors

• Cho Robert
• Stafford Jeffrey Alan

Classifications

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K38/15

  Depsipeptides; Derivatives thereof · CPC title

• A61K31/495

  having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) · CPC title